Parenteral drug delivery: 2

Pharmaceutical Journal

Volumn 263, Issue 7061, 1999, Pages 355-360

  Uchegbu, Ijeoma F ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; EMULSIFYING AGENT; PRODRUG;

DRUG CONJUGATION; DRUG IMPLANT; EMULSION; INJECTION; MICELLE; PARENTERAL DRUG ADMINISTRATION; REVIEW;

EID: 0033523412     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Florence AT, Attwood D. Physicochemical principles of pharmacy. 3rd ed. Hampshire: Macmillan Press, 1998.
2. Tarr BD, Sambandan TG, Yalkowsky SH. A new parenteral emulsion for the administration of taxol. Pharm Res 1987;4:162-5.
3. Strickley RG, Anderson BD. Solubilization and stabilization of an anti-HIV rhiocarbamate, NSC 629243, for parenteral delivery, using extemporaneous emulsions. Ibid 1993;10:1076-82.
4. Lundberg B. Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures. J Pharm Sci 1994;83:72-5.
5. Lundberg BB. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel(Taxol). J Pharm Pharmacol 1997;49:16-21.
6. Prankerd RJ, Stella VJ. The use of oil-in-water emulsions as a vehicle for parenteral drug administration. J Parent Sci Tech 1990;44:139-49.
7. Floyd AG. Top ten considerations in the development of parenteral emulsions. PSTT 1999;2:134-43.
8. Lee MJ, Lee MH, Shim CK. Inverse targeting of drugs to reticuloendothelial system-rich organs by lipid microemulsion emulsified with Poloxamer-338. Int J Pharm 1995;113:175-87.
9. Liu F, Liu D. Long circulating emulsions (oil-in-water) as carriers for lipophilic drugs, Pharm Res 1995;12:1060-4.
10. Song YK, Liu DX, Maruyama K, Takizawa T. Antibody mediated lung targeting of long-circulating emulsions. PDA J Pharmaceut Sci Tech 1996;50:372-7.
11. Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman JP, D'Athis M, et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992;305:921-5.
12. Albers E, Muller BW. Cyclodextrin derivatives in pharmaceutics. Crit Rev Therap Drug Carr Sys 1995;12:311-37.
13. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation. J Pharm Sci 1997;86:147-62.
14. Brewster ME, Hora MS, Simpkins JW, Bodor N. Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm Res 1991;8:792-5.
15. Pitha J, Gerloczy A, Olivi A. Parenteral hydroxypropyl cyclodextrins - intravenous and intracerebral administration of lipophiles. J Pharm Sci 1994;83:833-7.
16. Stella VJ, Lee HK, Thompson DO. The effect of Sbe4-Beta-Cd on IV methylprednisolone pharmacokinetics in rats - comparison to a cosolvent solution and 2 water-soluble prodrugs. Int J Pharm 1995;120:189-95.
17. Loscher W, Honack D, Richter A, Schulz HU, Schurer M, Dusing R, et al. New injectable aqueous carbamazepine solution through completing with 2-hydrosypropyl-beta-cyclodextrin - tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. Epilepsia 1995;36:255-61.
18. Yoshida A, Yamamoto M, Itoh T, Irie T, Hirayama F, Uekama K. Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine. Chem Pharm Bull (Tokyo) 1990;38:176-9.
19. Trapani G, Latrofa A, Franco M, Lopedota A, Sanna E, Liso G. Inclusion complexation of propofol with 2-hydroxypropyl-beta-cyclodextrin. Physicochemical, nuclear magnetic resonance spectroscopic studies, and anesthetic properties in rat. J Pharm Sci 1998;87:514-8.
20. McCormack B, Gregoriadis G. Drugs-in-cyclodextrins-in-liposomes: an approach to controlling the fate of water insoluble drugs in vivo. Int J Pharm 1998;162:59-69.
21. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Rogers GT, Burke PJ, et al. Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibod Immunoconj Radiopharm 1991;4:915-22.
22. Martin J, Stribbling SM, Poon GK, Begent RHJ, Napier M, Sharma SK, et al. Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol 1997;40:189-201.
23. Sharma SK. Immune response in ADEPT. Adv Drug Del Rev 1996;22:369-76.
24. Bagshawe KD, Sharma SK, Springer CJ. Rogers GT. Antibody-directed enzyme prodrug therapy (ADEPT) - review. Ann Oncol 1994;5:879-91.
25. Wolfe LA, Mullin RJ, Laethem R, Blumenkopf TA, Cory M, Miller JF, et al. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: In vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Bioconj Chem 1999;10:38-48.
26. Ringsdorf H. Structure and properties of pharmacologically active polymers, J Polym Sci Polym Symp 1975;51:135-53.
27. Hurwitz E, Wilchek M, Pitha J. Soluble macromolecules as carriers of daunorubicin. J Appl Biochem 1980;2:25-30.
28. Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J, et al. Tumor tropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16/F10 melanoma. Br J Cancer 1994;70:636-41.
29. Maeda M, Takasuka N, Suga T, Uehara N, Hoshi A. Antitumor-activity of a new series of platinum complexes - trans(+/-)-1,2-cyclohexanediammineplatinum(Ii) conjugated to acid polysaccharides. Anti-Cancer Drugs 1993;4:167-71.
30. Nichifor M, Schacht EH, Seymour LW. Polymeric prodrugs of 5-fluorouracil. J Control Rel 1997;48:165-78.
31. Sinn H, Schrenk HH, Friedrich EA, Schilling U, Maier-Borst W. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part 1. Nucl Med Biol 1990;17:819-27.
32. Matsumara Y, Maeda H. A new concept for macromolecular therapeutics in cancer therapy; mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res 1986;46:6387-92.
33. Pimm MV, Perkins AC, Strohalm J, Ulbrich K, Duncan R. Gamma-scintigraphy of the biodistribution of I-123 labelled N-(2- hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary-carcinoma, J Drug Target 1996;3:375-83.
34. Soyez H, Seymour LW, Schacht E. Macromolecular derivatives of N,N-di-(2-chloroethyl)-4-phenylene diamine mustard. 2. In vitro cytotoxicity and in vivo anticancer efficacy. J Control Rel 1999;57:187-96.
35. Yeung TK, Hopewell JW, Simmonds RH, Seymour LW, Duncan R, Bellini O, et al. Reduced cardiotoxicity of doxorubicin given in the form of N-(2- hydroxypropyl)methacrylamide conjugates - an experimental-study in the rat. Cancer Chemother Pharmacol 1991;29:105-11.
36. Vasey PA, Duncan R, Twelves C, Kaye SB, Strolin-Benedetti M, Cassidy J. Clinical and pharmacokinetic phase I study of PK1 (HPMA co-polymer doxorubicin). Proceedings of the 9th NCI-FORTC symposium on new drugs in cancer therapy, Amsterdam, 1996, p338.
37. Seymour LW, Ulbrich K, Wedge SR, Hume IC, Strohalm J, Duncan R. N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor - pharmacokinetics in DBA2 mice. Br J Cancer 1991;63:859-66.
38. Hirabayashi H, Nishikawa M, Takakura Y, Hashida M. Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery. Pharm Res 1996;13:880-4.
39. Omelyanenko V, Kopeckova P, Gentry C, Shiah JG, Kopecek J. HPMA copolymer-anticancer drug OV-TL16 antibody conjugates. 1. Influence of method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target 1996,3:357-73.
40. Pimm MV, Perkins AC, Strohalm J, Ulbrich K, Duncan R. Gamma-scintigraphy of a I-123 labelled n-(2- hydroxypropyl)-methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude-mice bearing hepatic human colon-carcinorna. Ibid 1996;3:385-90.
41. Kerr DJ, Seymour LW, Boivin C, Julyan P, Doran J, David M, et al. Phase I clinical trial of HPMA copolymers bearing doxorubicin and galactosamine. 3rd international symposium on polymer therapeutics, London, 1998.
42. Kabanov AV, Batrakova EV, Melik-Nubarov NS, Fedoseev NA, Dorodnich Y, Alakhov VY, et al. A new class of drug carriers; micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microtainers for drug targeting from blood in brain. J Control Rel 1992;22:141-58.
43. Batrakova EV, Dorodnych TY, Klinskii EY, Kliushnenkova EN, Shemchukova OB, Goncharova ON, et al. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: In vivo evaluation of anti-cancer activity. Br J Cancer 1996;74:1545-52.
44. Yokayama M, Miyauchi M, Yamada N, Okano T, Kataoka K, Inoue S. Polymer micelles as novel drug carrier: adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. J Contr Rel 1990;11:269-78.
45. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles as vehicles for drug delivery. Ibid 1993;24:119-32.
46. Kwon GS, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Biodistribution of micelle-forming polymer drug conjugates. Pharm Res 1993;10:970-4.
47. Kwon G, Suwa S, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J Control Rel 1994;29:17-23.
48. Garvin KL, Miyano JA, Robinson D, Giger D, Novak J, Radio S. Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis. A canine model. J Bone Joint Surg. Am Vol 1994;76:1500-6.
49. Fujita T, Tamura T, Yamada H, Yamamoto A, Muranishi S. Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice. J Drug Target 1997;4:289-96.
50. Labhasetwar V, Underwood T, Gallagher M, Murphy G, Langberg J, Levy RJ. Sotalol controlled-release systems for arrhythmias - in-vitro characterization, in-vivo drug disposition, and electrophysiologic effects. J Pharm Sci 1994;83:156-64.
51. Reinhard CS, Radomsky ML, Saltzman WM, Hilton J, Brem H. Polymeric controlled release of dexamethasone in normal rat-brain. J Control Rel 1991;16:331-40.
52. Moo-Young AJ, Kuzuma P, Quandt H, Shlegel PN, Bardin CW, Frick J, et al. Clinical response to a 12 month histrelin hydrogel implant for the treatment of prostate cancer. Proc Int Symp Control Rel Bioact Mater 1998;25:64-5.
53. Lesser GJ, Grossman SA, Leong KW, Lo HN, Eller S. In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain. Pain 1996;65:265-72.
54. Suhonen SP, Allonen HO, Lähteenmäki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995;172:562-7.
55. Bernatchez SF, Merkli A, Tabatabay C, Gurny R, Zhao QH, Anderson JM, et al. Biotolerance of a semisolid hydrophobic biodegradable poly(ortho ester) for controlled drug delivery. J Biomed Mater Res 1993;27:677-81.
56. Chandrashekar G, Udupa N. Biodegradable injectable implant systems for long term drug delivery using poly(lactic-co-glycolic) acid copolymers. J Pharm Pharmacol 1996;48:669-74.
57. Haglund BO, Josi R, Himmelstein KJ. An in situ gelling system for parenteral delivery. J Control Rel 1996;41:229-35.
58. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997;388:860-2.
59. Joshi R, Arora V, Desjardins JP, Robinson D, Himmelstein KJ, Iversen PL. In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugs. Pharm Res 1998;15:1189-95.
60. Chen J, Jo S, Park K, Polysaccharide hydrogels for protein drug delivery. Carbohydrate Polym 1995;28:69-76.
61. Kunou N, Ogura Y, Hashizoe M, Honda Y, Hyon SH, Ikada Y. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J Control Rel 1995;37:143-50.
62. Meyer J, Whitcomb L, Treuheit M, Collins D. Sustained in-vivo activity of recombinant human granulocyte-colony- stimulating factor (RHG-CSF) incorporated into hyaluronan. Ibid 1995;35:67-72.
63. Kagatani S, Shinoda T, Konno Y, Fukui M, Ohmura T, Osada Y. Electroresponsive pulsatile depot delivery of insulin from poly(dimethylaminopropylacrylamide) gel in rats. J Pharm Sci 1997;86:1273-7.
64. Mestiri M, Benoit JP, Hernigou P, Devissaguet JP, Puisieux F. Cisplatin-loaded poly(methyl methacrylate) implants - a sustained drug-delivery system. J Control Rel 1995;33:107-13:
65. Suisha F, Kawasaki N, Miyazaki S, Shirakawa M, Yamatoya K, Sasaki M, et al. Xyloglucan gels as sustained release vehicles for the intraperitoneal administration of mitomycin C. Int J Pharm 1998;172:27-32.
66. Seymour LW, Duncan R, Duffy J, Ng SY, Heller J. Poly(ortho ester) matrices for controlled-release of the antitumor agent 5-fluorouracil. J Control Rel 1994;31:201-6.
67. Imasaka K, Yoshida M, Fukuzaki H, Asano M, Kumakura M, Mashimo T, et al. New biodegradable polymers of L-lactic acid and aromatic hydroxy-acids and their applications in drug delivery svstems. Int J Pharm 1992;81;31-8.
68. Anderson FD, Archer DF, Harman SM, Leonard RJ, Wilborn WH. Tissue-response to bioerodible, subcutaneous drug implants - a possible determinant of drug absorption kinetics. Pharm Res 1993;10:369-80.
69. Rogge MC, Charenkavanich S, DiBiase M, Jones W, Knox SJ, Alam JJ. Impaired bioavailability of interferon beta-1a when administered intramuscularly by needle-free injection. Drug Delivery 1998;5:275-80.
70. Degano P, Sarphie DF, Bangham CRM. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect(R) system. Vaccine 1998;16:394-8.
71. Coming soon . . . "near-to-market" novel drug delivery systems. Pharm J 1998;261:509.
72. Verrips GH, Hirasing RA, Fekkes M, Vogels T, Verloove Vanhorick SP, DelemarreVandeWaal HA. Psychological responses to the needle-free Medi-Jector(R) or the multidose Disetronic(R) injection pen in human growth hormone therapy. Acta Paediatrica 1998;87:154-58.
73. Prybylski D, Santana S, Englender S, Smith M. A prospective evaluation of the acceptability of a needle-free jet injector in a routine immunization setting. Am J Epidemiol 1994;139:S71.
74. Florentine BD, Frankel K, Raza A, Cobb CJ, Greaves T, Carriere C, et al. Local anesthesia for fine-needle aspiration biopsy of palpable breast masses: The effectiveness of a jet injection system. Diagnostic Cytopathol 1997;17:472-6.
75. Domino EF, Zsigmond EK, Kovacs V, Fekete G, Stetson P. A new route, jet injection for anesthetic induction in children .3. Ketamine pharmacokinetic studies. Int J Clin Pharmacol Ther 1997;35.527-30.
76. Bennett J, Nichols F, Rosenblum M, Condry J. Subcutaneous administration of midazolam: A comparison of the Bioject jet injector with the conventional syringe and needle. J Oral Maxillofac Surg 1998;56:1249-54.
77. Zsigmond EK, Darby P, Koenig HM, Goll E. V. A new route, jet injection of lidocaine for skin wheat for painless intravenous catheterization. Int J Clin Pharmacol Therap 1999;37:90-9.
78. Partsch CJ, vonBuren E, Kuhn B, Sippell WG, Brinkmann G. Visualization of injection depot after subcutaneous administration by syringe and needle-free device (-Medi-Jector): first results with magnetic resonance imaging. Eur J Pediatr 1997;156:893-94.
79. Houdijk E, Herdes E, DelemarreVandeWaal HA. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency. Acta Paediatrica 1997;86:1301-7.
80. Gerbert J, Burns S, Liedtke LA. Anesthesia blocks of the lower extremity - Comparing the Biojector(R) with needle and syringe. J Am Podiatric Med Assoc 1996;86:195-204.
81. Domino EF, Zsigmond EK, Kovacs V, Olajos B, Fekete G. A new route, jet injection for anesthetic induction in children. IV. Midazolam plasma levels. Int J Clin Pharmacol Ther 1998;36: 458-62.
82. Seyam RM, Begin LR, Tu LM, Dion SB, Merlin SL, Brock GB. Evaluation of a no-needle penile injector: A preliminary study evaluating tissue penetration and its hemodynamic consequences in the rat. Urology 1997;50:994-8.
83. Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge, Virology 1998;246:134-44.
84. Fox S. Hepatitis B vaccine deal - PowderJect and Glaxo sign DNA vaccine agreement. Genetic Engineer News 1998;18:24 et seq.